clobazam has been researched along with Anxiety Neuroses in 23 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days)." | 5.40 | Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. ( Bekersky, I; Harris, SI; Isojarvi, J; Lee, D; Tolbert, D, 2014) |
| "The results of treatment of neurotic disorders with single or divided daily doses of the anxiolytic drug clobazam have been compared." | 5.05 | Clobazam: single or divided doses? ( Arnau, C; Costa Molinari, JM; Piña, C; Vallvé, C, 1982) |
| "Clobazam1 is a 1,5-benzodiazepine with antianxiety and anticonvulsant properties, advocated for the treatment of primary anxiety and that associated with organic or functional disorders." | 3.75 | Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1980) |
| "Clobazam was well tolerated at the doses used with the few side-effects recorded as mild to moderate." | 2.66 | A short term open clinical trial of clobazam in the treatment of patients with panic attacks. ( Burrows, GD; Judd, FK; Marriott, PF; Norman, TR, 1989) |
| " It was speculated that the relatively high daily dosage of diazepam may have been contributed to these results." | 2.65 | Clobazam and diazepam in anxiety. ( Brown, AS; Cohen, D; Harris, H; Hurowitz, A; Lindenbaum, EJ; Rickels, K; Ross, HA; Weinstock, R; Wiseman, K; Zal, M, 1981) |
| "There was no tendency to physical drug dependence during treatment and during a one-week placebo phase after discontinuation of Psyton." | 2.65 | [Long-term treatment of depressive syndromes with Psyton (author's transl)]. ( Jellinger, K; Koeppen, D; Rössner, M, 1982) |
| "Clobazam is a 1,5-benzodiazepine that has been approved for use, in various parts of the world, as an add-on treatment for seizure disorders and as a treatment for anxiety." | 1.51 | Gestational Exposure to Benzodiazepines, 3: Clobazam and Major Congenital Malformations. ( Andrade, C, 2019) |
| "To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days)." | 1.40 | Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. ( Bekersky, I; Harris, SI; Isojarvi, J; Lee, D; Tolbert, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (78.26) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, C | 1 |
| Tolbert, D | 1 |
| Harris, SI | 1 |
| Bekersky, I | 1 |
| Lee, D | 1 |
| Isojarvi, J | 1 |
| Guran, P | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Petursson, H | 1 |
| Lader, MH | 1 |
| Rickels, K | 1 |
| Brown, AS | 1 |
| Cohen, D | 1 |
| Harris, H | 1 |
| Hurowitz, A | 1 |
| Lindenbaum, EJ | 1 |
| Ross, HA | 1 |
| Weinstock, R | 1 |
| Wiseman, K | 1 |
| Zal, M | 1 |
| Obel, AO | 1 |
| Kabes, J | 1 |
| Dostal, T | 1 |
| Balon, R | 1 |
| Jellinger, K | 1 |
| Koeppen, D | 1 |
| Rössner, M | 1 |
| Nicholson, AN | 1 |
| Arnau, C | 1 |
| Costa Molinari, JM | 1 |
| Piña, C | 1 |
| Vallvé, C | 1 |
| Lapierre, YD | 1 |
| Tremblay, A | 1 |
| Gagnon, A | 1 |
| Monpremier, P | 1 |
| Berliss, H | 1 |
| Oyewumi, LK | 1 |
| Smith, GA | 1 |
| Mikus, P | 1 |
| Jacobson, AF | 1 |
| Goldstein, BJ | 1 |
| Dominguez, RA | 1 |
| Steinbook, RM | 1 |
| Hertrich, O | 1 |
| Botter, PA | 1 |
| Frey, R | 1 |
| Böhm, C | 1 |
| Placchi, M | 1 |
| Stallone, F | 1 |
| Gammans, RE | 1 |
| Alms, DR | 1 |
| Shrotriya, RC | 1 |
| Robinson, DS | 1 |
| Ostrogonac, S | 1 |
| Vuckovic, S | 1 |
| Judd, FK | 1 |
| Burrows, GD | 1 |
| Marriott, PF | 1 |
| Norman, TR | 1 |
| Castillo, A | 1 |
| Sotillo, C | 1 |
| Mariategui, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
1 review available for clobazam and Anxiety Neuroses
| Article | Year |
|---|---|
Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Benzodiazepino | 1980 |
15 trials available for clobazam and Anxiety Neuroses
| Article | Year |
|---|---|
[Study in pediatrics of an anxiolytic drug: clobazam].
Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Child; Child Behav | 1976 |
Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Benzodiazepino | 1980 |
Clobazam and diazepam in anxiety.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clinical Trials a | 1981 |
Clinical trial with clobazam.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clinical Trials as Topic | 1981 |
[Long-term treatment of depressive syndromes with Psyton (author's transl)].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; | 1982 |
Clobazam: single or divided doses?
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Ad | 1982 |
A therapeutic and discontinuation study of clobazam and diazepam in anxiety neurosis.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clinical Trials a | 1982 |
[Effect on vigilance of a single administration of clobazam].
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Benzodiazepines; Benzodiazepinones; Cl | 1982 |
A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety.
Topics: Adult; Ambulatory Care; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; | 1983 |
Single daily dose treatment of anxiety with clobazam: a double-blind study versus normal multiple-dose treatment with diazepam.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; | 1980 |
[Demonstration of the central effects of D,L-kawain with EEG brain mapping].
Topics: Anti-Anxiety Agents; Anxiety Disorders; Arousal; Benzodiazepines; Benzodiazepinones; Brain Mapping; | 1991 |
A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Benzodiazepines; Benzodiazepinones; Buspiron | 1990 |
[Double-blind study of clobazam (Odipam) and diazepam in non-psychotic anxiety states].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Cloba | 1989 |
A short term open clinical trial of clobazam in the treatment of patients with panic attacks.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clini | 1989 |
Alprazolam compared to clobazam and placebo in anxious outpatients.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clini | 1987 |
8 other studies available for clobazam and Anxiety Neuroses
| Article | Year |
|---|---|
Gestational Exposure to Benzodiazepines, 3: Clobazam and Major Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Anxiety Disorders; Benzodiazepines; Clobazam; Drug Therapy, Combination | 2019 |
Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.
Topics: Adult; Aged; Anticonvulsants; Anxiety Disorders; Benzodiazepines; Clobazam; Drug-Related Side Effect | 2014 |
Withdrawal reaction from clobazam.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clobazam; Humans; | 1981 |
Practical therapeutics. Anxiolytic drugs.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clobazam; Diazepam; Huma | 1981 |
[Anxiolytics in man: studies on sleep and performance (author's transl)].
Topics: Anti-Anxiety Agents; Anxiety Disorders; Arousal; Attention; Benzodiazepines; Benzodiazepinones; Clob | 1982 |
Voice analysis of the effects of benzodiazepine tranquillizers.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Arousal; Benzodiazepines; Benzodiazepinones; Clobazam; Diaze | 1982 |
[Ataractic treatment in psychiatry and general medicine. Overview of preparations, 3].
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Chlorprothixene; Clobaza | 1983 |
Clobazam and panic disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Clobazam; Humans; Panic | 1991 |